机构:[1]Department of Urology, West ChinaHospital, Sichuan University, Chengdu,610041, People’s Republic of China[2]Institute of Urology, West ChinaHospital, Sichuan University, Chengdu,610041, People’s Republic of China
第一作者机构:[1]Department of Urology, West ChinaHospital, Sichuan University, Chengdu,610041, People’s Republic of China[2]Institute of Urology, West ChinaHospital, Sichuan University, Chengdu,610041, People’s Republic of China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Urology, West ChinaHospital, Sichuan University, Chengdu,610041, People’s Republic of China[2]Institute of Urology, West ChinaHospital, Sichuan University, Chengdu,610041, People’s Republic of China[*1]Department of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan, People’s Republic of China[*2]Department of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan, People’s Republic of China
推荐引用方式(GB/T 7714):
Xudong Zhu,Xingming Zhang,Guangxi Sun,et al.Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma.[J].Cancer management and research.2021,13:6833-6845.doi:10.2147/CMAR.S327029.
APA:
Xudong Zhu,Xingming Zhang,Guangxi Sun,Zhenhua Liu,Haoran Zhang...&Pengfei Shen.(2021).Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma..Cancer management and research,13,
MLA:
Xudong Zhu,et al."Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma.".Cancer management and research 13.(2021):6833-6845